Accuray Inc. announced its momentum in gaining adoption for both the new CyberKnife M6 Series and TomoTherapy H Series Systems at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Georgia World Congress Center in Atlanta. Through presentations from leading radiation oncology practitioners and product demonstrations, attendees can gain further knowledge on the clinical capabilities of the CyberKnife M6 Series and TomoTherapy H Series Systems introduced at last year’s ASTRO meeting.

Cisplatin High-Dose Brachytherapy Beneficial for Advanced Cervical Cancer ASTRO

Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.

iCAD Inc. has announced a strategic alliance with DermEbx to offer the Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers. 

Sensus Healthcare has announced its newest introduction for non-melanoma skin cancer treatment at the 55th annual American Society of Therapeutic Radiation Oncology (ASTRO) in Atlanta, Ga. Sensus has an advanced SRT-100 superficial radiotherapy platform, featuring SharpBeam and has introduced the recently FDA-cleared technology that now allows you to "See what you Treat." 

Mirada Medical has formalized an agreement with General Electric Healthcare, Milwaukee, Wis., whereby GE will license Mirada’s powerful automatic atlas-based contouring software for implementation on their AdvantageSim MD 9 virtual simulation software suite for advanced radiation therapy planning. The technology is based on Mirada Medical’s deformable registration software, which is widely regarded as best in class when aligning image data for RT planning.

An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also suggests that lung cancer patients who received intensity modulated radiation therapy (IMRT) reported less decline in their QOL compared to those receiving three-dimensional conformal radiation therapy (3-D CRT).

Cianna Medical Inc., announced results of two new studies showing excellent longer-term outcomes with the SAVI breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. A third study demonstrated SAVI’s ability to precisely deliver radiation while avoiding critical structures. SAVI is a strut-based applicator that delivers accelerated partial breast irradiation (APBI), a five-day course of targeted radiation for early-stage breast cancer.

IBA (Ion Beam Applications S.A.) has launched an extension to the Visicoil product line at the annual ASTRO congress of the American Society for Radiation Oncology. This new design incorporates kV X-ray imaging compliant Visicoil Linear Markers pre-loaded in 21g and 22g needles that are almost half the size of needles typically used for placement of gold seeds.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now